Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Introduction
2.1 Influenza
2.2 GBI Research Report Guidance
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Market Overview
3.1 Production Cycle for the Seasonal Influenza Vaccines
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market
3.3 Revenue Forecasts for the Seasonal Influenza Vaccine Market
3.4 Geographical Segmentation
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Geographical Landscape
4.1 Revenue Analysis by Geography
4.2 Australia
4.2.1 Vaccination Pattern
4.2.2 Cost of Vaccine
4.2.3 Total Revenue
4.3 New Zealand
4.3.1 Vaccination Pattern
4.3.2 Cost of Vaccine
4.3.3 Total Revenue
4.3.4 Major Players by Market Share
4.4 Taiwan
4.4.1 Vaccination Pattern
4.4.2 Cost of Vaccine
4.4.3 Total Revenue
4.4.4 Major Players by Market Share
4.5 Philippines
4.5.1 Vaccination Pattern
4.5.2 Cost of Vaccine
4.5.3 Total Revenue
4.5.4 Major Players by Market Share
4.6 Malaysia
4.6.1 Vaccination Pattern
4.6.2 Cost of Vaccine
4.6.3 Total Revenue
4.6.4 Major Players by Market Share
4.7 Hong Kong
4.7.1 Vaccination Pattern
4.7.2 Cost of Vaccine
4.7.3 Total Revenue
4.7.4 Major Players by Market Share
4.8 Singapore
4.8.1 Vaccination Pattern
4.8.2 Cost of Vaccine
4.8.3 Total Revenue
4.8.4 Major Players by Market Share
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Drivers and Restraints
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region
5.1.1 Threat of Pandemic Influenza
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines
5.1.3 Emergence of Novel Production Technologies and Vaccines
5.1.4 Population Growth
5.1.5 Economic Reasons
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market
5.2.2 Variable Demand
5.2.3 Limited Production Capacity
5.3 Australia
5.3.1 Drivers
5.3.2 Restraints
5.4 New Zealand
5.4.1 Drivers
5.4.2 Restraints
5.5 Taiwan
5.5.1 Drivers
5.5.2 Restraints
5.6 Philippines
5.6.1 Drivers
5.6.2 Restraints
5.7 Malaysia
5.7.1 Drivers
5.7.2 Restraints
5.8 Hong Kong
5.8.1 Drivers
5.8.2 Restraints
5.9 Singapore
5.9.1 Drivers
5.9.2 Restraints
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Regulatory Landscape
6.1 Registration Process and Regulations in Australia
6.2 Registration Process and Regulations in New Zealand
6.3 Registration Process and Regulations in Taiwan
6.4 Registration Process and Regulations in the Philippines
6.5 Registration Process and Regulations in Malaysia
6.6 Registration Process and Regulations in Hong Kong
6.7 Registration Process and Regulations in Singapore
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Pipeline Analysis
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development
7.2 Profiles for Promising Vaccines under Clinical Development
7.2.1 Optaflu
7.2.2 GSK2186877A
7.2.3 Intanza / Flu-ID
7.2.4 Fluad Pediatric
7.3 Research and Development Pipeline
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Competitive Landscape
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region
8.1.1 Fluarix
8.1.2 Vaxigrip
8.1.3 Influvac
8.1.4 Fluvax
8.1.5 Agrippal
8.2 Key Areas Focused for R&D
8.3 Competitive Profiling
8.3.1 Sanofi Pasteur
8.3.2 GlaxoSmithKline Biologicals
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals)
8.3.4 CSL Biotherapies
8.3.5 Novartis Vaccines
8.3.6 Adimmune Corporation
8.3.7 Crucell N.V. (Berna Biotech)
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region: M&A Landscape
9.1 Overview
9.1.1 AstraZeneca Acquires Medimmune
9.1.2 Sanofi Aventis Acquires Acambis
9.1.3 Mymetics Acquires Virosome Biologicals
9.1.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock
9.1.5 Novartis to Acquire a Majority Stake in Zhejiang Tianyuan
9.1.6 Abbott Laboratories Acquires Solvay Pharmaceuticals
9.1.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
9.1.8 Johnson & Johnson to Acquire a Majority Stake in Crucell
9.2 M&A Deals by Value
9.3 M&A Deals by Geography
9.4 R&D Licensing Agreements for the Period 2007-2010
9.4.1 Crucell Enters Into License Agreement With ADImmune
9.4.2 MedImmune Enters Into Licensing Agreement With Sanofi Pasteur
9.4.3 Vivalis Enters Into Licensing Agreement With GlaxoSmithKline
9.4.4 Vivalis Enters Into Licensing Agreement With Nobilon International
9.4.5 MedImmune Enters Into Licensing Agreement With GlaxoSmithKline
9.4.6 Hemispherx Biopharma Enters Into Licensing Agreement With BIKEN
9.4.7 MedImmune Enters Into Licensing Agreement With BIKEN
9.4.8 MedImmune Enters Into Licensing Agreement With Omninvest
9.4.9 OPKO Health Enters Into Licensing Agreement With Academia Sinica
9.4.10 AltraVax Enters Into Licensing Agreement With Maxygen
9.4.11 NasVax Announces Option Licensing Agreement With Novartis
9.4.12 iBio Enters Into Licensing Agreement With G-Con
9.4.13 Deals by Geography
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources